Changes of NLRP3 in serum and cerebrospinal fluid of patients after moderate to severe traumatic brain injury and their predictive values for prognosis

Wei Chen,Zhigang Wang,Gengfan Ye,Guangyao Zhu,Shiwei Li,Pandi Chen,Hongcai Wang,Shufeng Zou,Maosong Chen
DOI: https://doi.org/10.1111/cns.70009
2024-09-22
CNS Neuroscience & Therapeutics
Abstract:The study has provided that Levels of NLRP3, especially in the CSF on day 3 post‐injury, could serve as a potential biomarker for predicting prognosis in moderate to severe TBI patients. Early measurement of NLRP3 levels could provide valuable insights into patient outcomes and guide therapeutic strategies. Background Traumatic brain injury (TBI) remains a major concern for global health. Recent studies have suggested the role of NOD‐like receptor pyrin domain‐containing protein 3 (NLRP3), an inflammatory marker, in the cerebrospinal fluid (CSF) and serum as potential indicators of TBI prognosis. The objective of the study was to characterize NLRP3 as a clinically applicable tool for predicting the outcomes of TBI patients. Methods A total of 270 patients with moderate to severe TBI were included in this retrospective analysis. Serum and CSF samples were collected at 1‐, 3‐, 7‐, and 21‐day post‐injury to measure NLRP3 levels. The prognosis of patients was evaluated after 3 months using the Glasgow Outcome Scale (GOS). Patients were categorized into good prognosis (GOS score >3) and poor prognosis (GOS score ≤3) groups. The relationship between NLRP3 levels and prognosis was analyzed. Results Patients with poor prognosis had significantly elevated NLRP3 levels in their serum on days 1 and 3 post‐injury compared with those with a good prognosis. The difference was more pronounced during these early days compared with days 7 and 21. However, NLRP3 levels in CSF consistently showed a large difference between the two groups throughout the observation period. Receiver operating characteristic analysis revealed that the level of NLRP3 in the CSF on day 3 post‐injury had the highest predictive value for prognosis, with an area under the curve of 0.83, followed by the level of NLRP3 in the serum on day 3 post‐injury. Conclusions The levels of NLRP3, especially in the CSF on day 3 post‐injury, can serve as a potential biomarker for predicting prognosis in moderate to severe TBI patients. Early measurement of NLRP3 levels can provide valuable insights into patient outcomes and guide therapeutic strategies.
pharmacology & pharmacy,neurosciences
What problem does this paper attempt to address?